FBXO25

Across TCGA pan-cancer cohorts, FBXO25 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FBXO25 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher FBXO25 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FBXO25 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, STAD, and SKCM are the cancer types where FBXO25 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.195	0.676	.005	24	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
SKCM	DFS	Median	All	0.023	0.738	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.635	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FBXO25–LUSC (OS)

Open the LUSC breakdown →